I finished 6 rounds of the original clinical trial Lu177 PSMA-617 in 2022 with remarkable results. It was approved in the US a few months later as Pluvicto. Now, I will be one of the first patients to repeat the same 6 treatments, starting Sept. 3, 2024. Going into unknown territory, again. Beats dying without trying.